OVERVIEW
Happy Saturday

Welcome to the Stocktwits Top 25 Newsletter this week!
The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
Here are the Stocktwits Top 25 Lists for this week:

SPONSORED BY EIGENQ
Why the race to replace today’s encryption has already started
The encryption that protects government, financial and health data was not built for quantum computers. NIST finalized the replacements in 2024, and Washington set migration deadlines in 2026. The first, a key national-security procurement milestone for new system acquisitions, begins in January 2027. Meanwhile, data encrypted today can be collected now and decrypted later. EigenQ builds the hardware for the switch, and is planning to go public through a proposed merger with Silicon Valley Acquisition Corp. (Nasdaq: SVAQ).
*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.
Disclaimer: Important disclosures: https://svacquisitioncorp.com/eigenq
SPONSORED BY TRADR ETFS
ANT is trading. ANTT & ANTZ will let you trade your 2X view.
Now that ANT has begun trading, every feed on the street has a take. On Monday, you can trade yours. ANTT seeks 200% of Anthropic’s daily stock performance while ANTZ seeks -200%. Both are expected to begin trading on Cboe on Monday, November 23rd.
Here’s what sharp traders already know: newly listed stocks typically don’t have options listed for their first several trading days. While the ANT options chain doesn’t exist yet, ANTT and ANTZ offer a leveraged way to position long or short — each in a single ticker, with no margin account, no picking a strike price or choosing an expiry date.
Both funds reset daily and are built for traders managing a short-term view, not long-term holders. Returns beyond one day can differ significantly from 2X or -2X.
Leveraged ETFs involve significant risk. Consider objectives, risks, charges and expenses; read the pre-effective prospectus* at www.tradretfs.com/anthropic before investing.
*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.
* The information in this Prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This Prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer of sale is not permitted. See the pre-effective prospectus.

Mid-Cap / Micro-Cap Top Movers of the Week 🐶
The top of every list fell hard this week and mostly kept its rank anyway. The movement that mattered came from fresh earnings, a Phase 3 readout, and one takeover that turned into a drag.
$PANW ( ▼ 5.09% ) : Palo Alto Networks, S&P 500 #16 to #8: Fiscal Q1 revenue rose 39% to $3.44B, the full-year outlook went up, and the company added a $4.5B all-stock deal for Applied Compute. Risk: GAAP operating income fell to $96M from $309M as acquisition costs landed. Q1 results
$TGT ( ▼ 0.97% ) : Target, S&P 500 #22 to #12: Q3 adjusted EPS of $2.65 cleared the roughly $2.05 expected, with comps up 5.6% in the company’s best sales quarter in five years. Risk: about $0.50 of that EPS came from $301M in tariff refunds; the underlying quarter was closer to $2.15. Q3 results
$FTNT ( ▼ 5.25% ) : Fortinet, Nasdaq 100 #12 to #5: Q3 revenue grew 20% to $2.08B with billings up 29% to $2.34B, and management raised the full-year outlook. Risk: the year now rides on a Q4 billings guide of $2.78B to $2.93B, the seasonally biggest quarter. Q3 results
$SLS ( ▼ 8.08% ) : Sellas Life Sciences, Russell 2000 newcomer at #5: The Phase 3 REGAL trial met its primary endpoint in AML, with median overall survival of 24.0 months against 14.7 and a hazard ratio of 0.59. Risk: the readout is topline data from 126 patients, and the BLA is not expected until the first half of 2027. REGAL results
$LITE ( ▼ 13.94% ) : Lumentum, Nasdaq 100 #10 to #22: Momentum broke despite Q1 revenue up 137% to $1.26B and a December-quarter guide near $1.6B. Risk: Lumentum agreed to be acquired by Marvell on November 2, so the shares now trade on Marvell’s stock, which fell 22% this week. Q1 results
Next week’s swing factor: Wednesday’s PCE report, the inflation reading the Fed watches most, lands hours before the Thanksgiving break with a December rate hike nearly priced in. The week ahead

Get In Touch 📬
Want to see some change? Respond to this email and reach me, Kevin Travers, with feedback. Follow me on Stocktwits. Send me charts and ideas! Refer a friend for this quarter’s edition of The RIP Forecast 😎
Terms & Conditions 📝
Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍
Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋





